At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
00867 CMS
Market Closed 11-06 16:08:52
10.600
+0.020
+0.19%
High10.800Low10.020Vol3.96M
Open10.580D1 Closing10.580Amplitude7.37%
Mkt Cap25.79BTradable Cap25.79BTotal Shares2.43B
T/O42.10MT/O Rate0.16%Tradable Shares2.43B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
GlobeNewswire  ·  11-05 21:00
Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
GlobeNewswire  ·  11-05 20:15
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
Hong Kong Stock Movers: CMS Surges Over 4% as Innovative Drug Ruxolitinib Phosphate Cream Wins Singapore Marketing Approval
Stock News  ·  11-05 11:08
Hong Kong Stock Movers: CMS Surges Over 4% as Innovative Drug Ruxolitinib Phosphate Cream Wins Singapore Marketing Approval
CMS Pharma's Innovative Drug Ruxolitinib Phosphate Cream Wins Singapore Marketing Approval
Stock News  ·  11-04
CMS Pharma's Innovative Drug Ruxolitinib Phosphate Cream Wins Singapore Marketing Approval
China Medical System Unit Rxilient Medical Wins Singapore Approval for Vitiligo Cream
Reuters  ·  11-04
China Medical System Unit Rxilient Medical Wins Singapore Approval for Vitiligo Cream
China Medical System Holdings - Rxilient Medical Receives Hsa Approval for Nda of Ruxolitinib Phosphate Cream on Nov 3, 2026
THOMSON REUTERS  ·  11-04
China Medical System Holdings - Rxilient Medical Receives Hsa Approval for Nda of Ruxolitinib Phosphate Cream on Nov 3, 2026
Elite Founder Led Stocks To Own In October 2026
Simply Wall St.  ·  10-31
Elite Founder Led Stocks To Own In October 2026
Humana is the 'Biggest Winner' From CMS' Medicare Advantage Star Ratings Impact on 2028 Reimbursements, Oppenheimer Says
MT Newswires Live  ·  10-10
Humana is the 'Biggest Winner' From CMS' Medicare Advantage Star Ratings Impact on 2028 Reimbursements, Oppenheimer Says
Lantheus Holdings (LNTH) Gains CMS Reimbursement Win Following A Fair Value Debate
Simply Wall St.  ·  10-09
Lantheus Holdings (LNTH) Gains CMS Reimbursement Win Following A Fair Value Debate
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire  ·  10-01
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
China Medical System Says Singapore Share Transfer Agent to Rename to Ascentium Corporate Services from Oct. 1
Reuters  ·  10-01
China Medical System Says Singapore Share Transfer Agent to Rename to Ascentium Corporate Services from Oct. 1
CMS Announces Renaming of Singapore Share Transfer Agent to Ascentium Corporate Services
Bulletin Express  ·  09-30
CMS Announces Renaming of Singapore Share Transfer Agent to Ascentium Corporate Services
CMS Maintains Stable Share Structure in September 2026; Public Float Remains Compliant
Bulletin Express  ·  09-30
CMS Maintains Stable Share Structure in September 2026; Public Float Remains Compliant
CMS Announces Preliminary Medicare Payment Rates for Laboratory Services in 2027
MT Newswires Live  ·  09-22
CMS Announces Preliminary Medicare Payment Rates for Laboratory Services in 2027
Lazard Asset Management Raises Stake in CMS with 1.265 Million Share Purchase
Deep News  ·  09-16
Lazard Asset Management Raises Stake in CMS with 1.265 Million Share Purchase
China Medical System Gets China Nod for Lupus Erythematosus Drug Trial
MT Newswires  ·  09-14
China Medical System Gets China Nod for Lupus Erythematosus Drug Trial
CMS Secures Clinical Trial Green Light for Innovative Lupus Treatment Candidate
Stock News  ·  09-14
CMS Secures Clinical Trial Green Light for Innovative Lupus Treatment Candidate
China Medical System Holdings - CMS-D001 Granted Drug Clinical Trial Approval Notice by Nmpa on Sept 11, 2026
THOMSON REUTERS  ·  09-14
China Medical System Holdings - CMS-D001 Granted Drug Clinical Trial Approval Notice by Nmpa on Sept 11, 2026
CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
GlobeNewswire  ·  09-09
CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
GlobeNewswire  ·  09-03
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

Introduction

Company Name.
CMS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
China Medical System Holdings Limited is an investment holding company mainly engaged in the pharmaceutical products business. The Company operates its business through two segments. The Integrated Pharmaceuticals Portfolio segment is engaged in the research and development, manufacturing and sales of pharmaceutical products. The Skin Health Business segment is engaged in the promotion and sales of skin disease related pharmaceutical products.
Issue price:
--